PSA response to finasteride challenge in men with a serum PSA greater than 4 ng/ml and previous negative prostate biopsy: Preliminary study

Urology

Volumn 60, Issue 3, 2002, Pages 464-468

  Kaplan, Steven A ^a,c   Ghafar, Mohamed A ^a   Volpe, Michael A ^a   Lam, John S ^a   Fromer, Debra ^a   Te, Alexis E ^b  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; HUMAN; HUMAN TISSUE; INCIDENCE; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TRANSRECTAL ULTRASONOGRAPHY;

EID: 0036754301     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01760-0     Document Type: Article

References (28)

1. Jemal A., Thomas A., Murray T., et al. Cancer statistics, 2002. Ca Cancer J Clin. 52:2002;23-47.
2. Hodge K.K., McNeil J.E., Terris M.K., et al. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol. 142:1989;71-74.
3. Rabbani F., Stroumbakis N., Kava B.R., et al. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol. 159:1998;1247-1250.
4. Eskew L.A., Bare R.L., McCullough D.L. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol. 157:1997;199-202.
5. Presti J.C. Jr, Chang J.J., Bhargava V., et al. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies results of a prospective clinical trial . J Urol. 163:2000;163-167.
6. Borboroglu P.G., Comer S.W., Riffenburgh R.H., et al. Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol. 163:2000;158-162.
7. Babaian R.J., Toi A., Kamoi K., et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol. 163:2000;152-157.
8. Levine M.A., Ittmann M., Melamed J., et al. Two consecutive series of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol. 159:1998;471-475.
9. Keetch D.W., Catalona W.J., Smith D.S. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol. 151:1994;1571-1574.
10. McConnell J.D., Wilson J.D., George F.W., et al. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab. 74:1992;505-508.
11. Norman R.W., Coakes K.E., Wright A.S., et al. Androgen metabolism in men receiving finasteride before prostatectomy. J Urol. 150:1993;1736-1739.
12. McConnell J.D., Bruskewitz R., Walsh P.C., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 338:1998;557-563.
13. Stoner E., Finasteride Study Group . The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. J Urol. 147:1992;1298-1302.
14. Gormley G.J., Stoner E., Bruskewitz R.C., et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 327:1992;1185-1191.
15. Finasteride Study Group . Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate. 22:1993;291-299.
16. Stoner E., Finasteride Study Group . Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology. 43:1994;284-294.
17. Kirby R.S., Bryan J., Eardley I., et al. Finasteride in the treatment of benign prostatic hyperplasia a urodynamic evaluation . J Urol. 70:1992;65-72.
18. Tammela T.L.J., Kontturi M.J. Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia. J Urol. 149:1993;342-344.
19. Lepor H., Williford W.O., Barry M.J., et al. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group . The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med. 335:1996;533-539.
20. Guess H.A., Gormley G.J., Stoner E., et al. Effect of finasteride on prostate specific antigen review of available data . J Urol. 155:1996;3-9.
21. Gormley G.J., Ng J., Cook T., et al. Effect of finasteride on prostate-specific antigen density. Urology. 43:1994;53-58.
22. Marks L.S., Partin A.W., Gormley G.J., et al. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia. J Urol. 157:1997;2171-2178.
23. Keetch D.W., Andriole G.L., Ratliff T.L., et al. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin or watchful waiting. Urology. 50:1997;901-905.
24. Pannek J., Marks L.S., Pearson J.D., et al. Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia. J Urol. 159:1998;449-453.
25. Presti J.C., Fair W.R., Andriole G.L., et al. Multicenter, randomized, double-blind, placebo-controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J Urol. 148:1992;1201-1204.
26. Andriole G.L., Guess H.A., Epstein J.I., et al. PLESS Study Group . Proscar Long-Term Efficacy and Safety Study:Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer results of a randomized, double-blind, placebo-controlled clinical trial . Urology. 52:1998;195-201.
27. Oesterling J.E., Roy J., Agha A., et al. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer effects of finasteride . Urology. 50:1997;13-18.
28. Cote R.J., Skinner E.C., Salem C.E., et al. The effect of finasteride on the prostate gland in men with elevated serum prostate specific antigen (PSA) levels. Br J Cancer. 78:1998;413-418.